2023
41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials
Strober B, Kircik L, Green L, Lockshin B, Brown P, Tallman A. 41625 Tapinarof Cream 1% Once Daily (QD) for Plaque Psoriasis: Post Hoc Analysis of Physician Global Assessment x Body Surface Area (PGAxBSA) Composite for the PSOARING 1 and 2 Trials. Journal Of The American Academy Of Dermatology 2023, 89: ab92. DOI: 10.1016/j.jaad.2023.07.371.Peer-Reviewed Original Research
2022
Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
Strober B, Armstrong A, Rubant S, Patel M, Wu T, Photowala H, Crowley J. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. Journal Of Dermatological Treatment 2022, 33: 2991-2996. PMID: 35839335, DOI: 10.1080/09546634.2022.2095328.Peer-Reviewed Original ResearchConceptsPsoriasis Area Severity IndexPASI 75Plaque psoriasis patientsSevere plaque psoriasisSub-optimal respondersPost Hoc AnalysisSignificant safety eventsPASI 50Plaque psoriasisBiologic therapyPASI scorePsoriasis patientsWashout periodIncomplete responsePatientsSafety eventsSeverity IndexPsoriasisDosesSuboptimal resultsSignificant safety riskDLQIAdalimumabPartial success